Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
  • Identify the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL
  • Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)
  • Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL
  • Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
  • Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
  • Evaluate the first line therapy options for chronic myeloid leukemia (CML) in chronic phase
  • Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML
  • Recognize the time-based response milestones and monitoring in patients with CML